The landscape of venture capital in the United States is undergoing a significant transformation, particularly within the biotech sector. According to recent data from Crunchbase, the share of U.S. startup investment allocated to biotech companies has plummeted to its lowest level in over two decades, accounting for just over 8% of total funding in 2025. This marks a stark contrast to previous years when biotech consistently commanded a double-digit percentage of venture capital, often exceeding 15% and peaking at around 20% in 2020.
As of now, investors have poured approximately $16.6 billion into biotech startups across seed through growth-stage rounds in 2025. This figure not only represents a significant decline in percentage terms but also indicates a downward trend in dollar amounts compared to prior years. While overall venture investment across various sectors has been on the rise, biotech funding appears to be lagging behind, raising concerns about the future viability of this critical industry.
Historically, biotech has been a robust sector for venture capital, attracting substantial investments due to its potential for groundbreaking innovations in healthcare and medicine. However, the current climate suggests a shift in investor sentiment, with many turning their attention toward artificial intelligence (AI) and other emerging technologies. The voracious appetite for AI startups has overshadowed traditional sectors like biotech, leading to a reallocation of funds that could have otherwise supported life sciences innovation.
One of the most alarming trends is the slowdown in early-stage funding for biotech companies. So far in 2025, U.S. biotech startups have raised only $8.2 billion in seed and early-stage funding, which is on track to be the lowest total in years. This decline in early-stage investment poses a significant risk to the pipeline of future biotech companies ready to scale and bring innovative therapies to market. Without sufficient early-stage funding, the industry may face a shortage of new entrants capable of driving advancements in drug discovery and medical technology.
The IPO landscape for biotech has also been lackluster in 2025. Only 18 funded U.S. startups in the biotech, drug discovery, and medical device spaces have made their public debuts on major exchanges such as Nasdaq or the New York Stock Exchange. This figure represents the lowest number of biotech IPOs in years, further underscoring the challenges facing the sector. The sluggish pace of IPOs is indicative of a broader trend where investors are becoming increasingly risk-averse toward biotech and medtech ventures.
Several factors contribute to this cautious approach among investors. One significant concern is the uncertainty surrounding public research funding, which has seen cuts in recent years. Additionally, leadership upheaval at the U.S. Food and Drug Administration (FDA) and ongoing debates regarding drug pricing policy have created an environment of unpredictability that makes investors wary of committing capital to biotech ventures. These factors collectively contribute to a climate where investors are more inclined to seek opportunities in sectors perceived as less risky, such as AI.
The AI sector, in stark contrast to biotech, has experienced an unprecedented surge in investment. In the first half of 2025 alone, nearly $90 billion has been funneled into North American AI deals. A significant portion of this funding can be attributed to high-profile rounds, including OpenAI’s staggering $40 billion financing led by SoftBank. As AI continues to capture headlines and attract massive investments, biotech finds itself struggling to compete for attention and resources.
Despite the challenges, there are still notable success stories within the biotech space. Some standout early-stage financings in 2025 include Kardigan, which raised $300 million for its cardiovascular drug development efforts; Lila Sciences, which secured $235 million for its scientific superintelligence technology; and Dispatch Bio, which raised $216 million for its immunotherapy initiatives. These examples highlight that while the overall trend may be concerning, there are still pockets of innovation and investment within the biotech sector.
However, the overarching narrative remains one of caution and contraction. The shrinking share of funding going to biotech is not solely a reflection of waning investor enthusiasm; it is also indicative of a broader shift in priorities as capital flows increasingly favor AI and related technologies. Historically, biotech companies have secured some of the largest venture rounds in any given quarter, but they are currently unable to compete with the fundraising prowess of AI giants.
The implications of this shift extend beyond immediate funding concerns. A decline in biotech investment could stifle innovation in critical areas such as drug development, personalized medicine, and medical devices. As the industry grapples with these challenges, it must also contend with the potential long-term consequences of reduced funding and fewer successful IPOs.
In conclusion, the current state of biotech funding in the United States paints a complex picture. While the sector has historically been a cornerstone of innovation in healthcare, it now faces significant headwinds as investor interest shifts toward AI and other emerging technologies. The decline in both funding and IPO activity raises important questions about the future of biotech and its ability to continue delivering transformative solutions for patients and healthcare systems. As the industry navigates this challenging landscape, it will be crucial for stakeholders to advocate for policies that support research funding, regulatory stability, and investment in the life sciences to ensure that biotech remains a vital contributor to global health and innovation.